Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets

Gupta, Subash C.; Tripathi, Yashoda Nandan

doi:10.1002/ijc.30546

Cited by 421 publications

(275 citation statements)

References 148 publications

(258 reference statements)

Supporting

Mentioning

260

Contrasting

Order By: Relevance

“…Triple‐negative breast cancer is a heterogeneous disease at the cellular, molecular, and clinical levels (Lehmann et al ., ). Long non‐coding RNA have recently emerged as important players implicated in relevant biological processes (Martin and Chang, ) as well as potential cancer biomarkers or therapeutic targets (Arun et al ., ; Chandra Gupta and Nandan Tripathi, ; Prabhakar et al ., ; Wan et al ., ; Wu and Du, ). In the present study, we classified TNBC using mRNA expression profiles (Chen et al ., ) and identified several lncRNA expressed in specific tumor subtypes.…”

Section: Discussionmentioning

confidence: 99%

Expression of long non‐coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple‐negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death

et al. 2019

View full text Add to dashboard Cite

Triple negative breast cancer ( TNBC ) represents an aggressive phenotype with poor prognosis compared with ER , PR, and HER 2‐positive tumors. TNBC is a heterogeneous disease, and gene expression analysis has identified seven molecular subtypes. Accumulating evidence demonstrates that long non‐coding RNA (lnc RNA ) are involved in regulation of gene expression and cancer biology, contributing to essential cancer cell functions. In this study, we analyzed the expression profile of lnc RNA in TNBC subtypes from 156 TNBC samples, and then characterized the functional role of Lnc KLHDC 7B ( ENSG 00000226738 ). A total of 710 lnc RNA were found to be differentially expressed between TNBC subtypes, and a subset of these altered lnc RNA were independently validated. We discovered that Lnc KLHDC 7B ( ENSG 00000226738 ) acts as a transcriptional modulator of its neighboring coding gene KLHDC 7B in the immunomodulatory subtype. Furthermore, Lnc KLHDC 7B knockdown enhanced migration and invasion, and promoted resistance to cellular death. Our findings confirmed the contribution of Lnc KLHDC 7B to induction of apoptosis and inhibition of cell migration and invasion, suggesting that TNBC tumors with enrichment of Lnc KLHDC 7B may exhibit distinct regulatory activity, or that this may be a generalized process in breast cancer. Additionally, in silico analysis confirmed for the first time that the low expression of KLHDC 7B and Lnc KLHDC 7B is associated with poor prognosis in patients with breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of long non‐coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple‐negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Another method is based on the usage of antisense oligonucleotides (ASOs) that are either short single-stranded RNAs or DNAs antisense to their target lncRNA [91]. Moreover, the use of small molecules can, for example, inhibit the interaction of HOTAIR with LSD1 and PRC2 [92,93]. The therapeutic usage of H19-regulated double-stranded DNA plasmid BC-819 has already been successfully tested in patients with bladder cancer [94].…”

Section: Discussionmentioning

confidence: 99%

Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer

Smolle

Bauernhofer

Pummer

et al. 2017

IJMS

View full text Add to dashboard Cite

The importance of long non-coding RNAs (lncRNAs) in the pathogenesis of various malignancies has been uncovered over the last few years. Their dysregulation often contributes to or is a result of tumour progression. In prostate cancer, the most common malignancy in men, lncRNAs can promote castration resistance, cell proliferation, invasion, and metastatic spread. Expression patterns of lncRNAs often change during tumour progression; their expression levels may constantly rise (e.g., HOX transcript antisense RNA, HOTAIR), or steadily decrease (e.g., downregulated RNA in cancer, DRAIC). In prostate cancer, lncRNAs likewise have diagnostic (e.g., prostate cancer antigen 3, PCA3), prognostic (e.g., second chromosome locus associated with prostate-1, SChLAP1), and predictive (e.g., metastasis-associated lung adenocarcinoma transcript-1, MALAT-1) functions. Considering their dynamic role in prostate cancer, lncRNAs may also serve as therapeutic targets, helping to prevent development of castration resistance, maintain stable disease, and prohibit metastatic spread.

show abstract

“…With the development of high‐throughput sequencing technology, it has been revealed that the non‐coding RNA (ncRNA) accounted for more than 95% of the human genome, and the complex interaction between the protein encoding RNA and functional ncRNA played an important role in the occurrence and development of HCC . Long ncRNA (lncRNA), as one of the important components of ncRNA, has been paid more and more attention to, which has been shown to be involved in epigenetic, gene transcription, post transcriptional regulation, and translation and has potential as a marker for early disease diagnosis …”

Section: Introductionmentioning

confidence: 99%

LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR‐24‐3p

Fan

Zeng

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cancer susceptibility candidate 2 (CASC2), a recently discovered long non-coding RNA (lncRNA), was confirmed to play numerous roles in several human cancers. However, the involvement and concrete mechanism of CASC2 in hepatocellular carcinoma (HCC) still need to be further elucidated. The relative expressions of CASC2 and miR-24-3p in HCC tissue and cell lines were determined by quantitative real-time PCR (qRT-PCR). The effects of CASC2 and miR-24-3p on HCC cells were further assessed via cell viability and apoptosis. In vivo tumorigenesis assay was performed to verify the inhibition effect of CASC2 on the tumor growth and further clarify the important role of miR-24-3p in this mechanism. Compared with the paired normal tissues, the relative expression of CASC2 significantly reduced in the HCC tissues, while miR-24-3p as determined by qRT-PCR obviously increased in the HCC tissues. This observation was also found in HCC cell lines. Meanwhile, the expression of CASC2 was negatively related to miR-24-3p expression in the HCC tissues (r = -0.804, P < 0.001). CASC2 could negatively regulate the expression of miR-24-3p in vitro. Moreover, CASC2 overexpression resulted in the growth inhibitory and apoptosis-inducing effects on HCC cells, but the up-regulation of miR-24-3p greatly eliminated the CASC2-induced effects. The tumorigenesis of HCC cells was restrained significantly by CASC2 overexpression as shown by decreased tumor volume and growth rate. However, miR-24-3p up-regulation rescued the inhibition of CASC2 on the tumor growth in tumor-bearing mice. LncRNA CASC2 inhibited the viability and induced the apoptosis of HCC cells through regulating miR-24-3p.

show abstract

Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets

Cited by 421 publications

References 148 publications

Expression of long non‐coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple‐negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death

Expression of long non‐coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple‐negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death

Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer

LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR‐24‐3p

Contact Info

Product

Resources

About